A
Alessandro Liberati
Researcher at University of Modena and Reggio Emilia
Publications - 145
Citations - 200037
Alessandro Liberati is an academic researcher from University of Modena and Reggio Emilia. The author has contributed to research in topics: Health care & Breast cancer. The author has an hindex of 46, co-authored 144 publications receiving 167184 citations. Previous affiliations of Alessandro Liberati include Mario Negri Institute for Pharmacological Research & Cochrane Collaboration.
Papers
More filters
Journal ArticleDOI
Health policies on drug dependence must be based on scientific evidence
TL;DR: Differences between the approaches of the Netherlands and Italy lead us to doubt that this is happening as scientific evidence on the effectiveness of interventions for drug dependence is increasingly available and should be used to inform policies.
Journal ArticleDOI
Oestrogen Receptor Status and Risk Factors for Breast Cancer
TL;DR: The present findings suggest that some epidemiological differences exist between ER+ and ER- breast cancer patients; however, large uncertainties emerge in the authors' and previous studies, suggesting the need for further biologic and epidemiologic research to better define the clinical and biological significance of hormonal receptor status.
Journal ArticleDOI
Performance of general hospitals in delivering adjuvant chemotherapy to breast cancer patients
Roldano Fossati,C. Confalonieri,Giovanni Apolone,Antonio Nicolucci,Gianni Tognoni,W Torri,Alessandro Liberati,P. Gosso,D. Tagliati,F. Di Vito,F. Grasso,P. A. Nannicini,M. Rinaldini,G. Di Biagio,M. Belli,G. Colantuoni,T. Pedicini,R. Vincenti,M. Fumagalli,G. Gritti +19 more
TL;DR: Overall the study suggests that adjuvant chemotherapy for breast cancer has entered general practice and can be satisfactorily delivered at the community level, however, better guidelines need to specify more precisely the treatment indications, regimen type and treatment duration.
Journal ArticleDOI
Eradicating Helicobacter pylori in non-ulcer dyspepsia may not be cost effective.
Giulio Formoso,Emilio Maestri,Nicola Magrini,Maurizio Koch,Lucio Capurso,Alessandro Liberati +5 more
TL;DR: Finding that patients with dyspepsia gain modest benefits from eradication of Helicobacter pylori, Moayyedi et al conclude that this intervention “may be cost effective,” but the risks associated with the antibiotic treatment are not taken into account.